1-10 of 10
Giles Best, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Devinder Gill, MD MRCP, FRCPath, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rosemary Anne Harrup, MD, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Oliver Giles Best, PhD BSc, Bryone Jean Kuss, PhD BMBS, FRCPA, FRACP
Journal: Blood
Blood (2018) 132 (Supplement 1): 4432.
https://doi.org/10.1182/blood-2018-99-114064
Published: 2018
Journal Articles

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

Kyle R Crassini, MBBS, BSc, Yandong Shen, BMedSc (Hon), William S. Stevenson, MBBS, PhD, Stephen P. Mulligan, PhD, FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc, Richard Christopherson, PhD Emeritus Professor
Journal: Blood
Blood (2018) 132 (Supplement 1): 1850.
https://doi.org/10.1182/blood-2018-99-118264
Published: 2018
Journal Articles

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS, BSc, Michael E O'Dwyer, MD, Michael Francis O'Neill, PhD BA, Richard Christopherson, PhD Emeritus Professor, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 1870.
https://doi.org/10.1182/blood-2018-99-115574
Published: 2018
Journal Articles

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Jane A. Freeman, BA, FRACP, FRCPA, MBBS, MPhil, MSc, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Richard Eek, MBCHB, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Nicholas E. Murphy, FRCPA, MBBS, FRACP, Duncan P. Carradice, MBBS, FRCPA, FRACP, Ann C. Solterbeck, BSc(hons) MSc PhDAStat, Oliver Giles Best, PhD BSc, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP
Journal: Blood
Blood (2018) 132 (Supplement 1): 3144.
https://doi.org/10.1182/blood-2018-99-116287
Published: 2018
Journal Articles

ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment

Narjis Rizwan, BSMedTech, MPhil, PhD, Yandong Shen, BMedSc (Hon), Edwin Iwanowicz, PhD, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Kyle R Crassini, MBBS, BSc, Richard Christopherson, PhD Emeritus Professor, Oliver Giles Best, PhD BSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 3145.
https://doi.org/10.1182/blood-2018-99-115555
Published: 2018
Journal Articles

Epigenetic Regulation of ZAP70 in Chronic Lymphocytic Leukemia.

Anton Parker, Shilu Amin, Tricia Zwiefelhofer, Ben Gregory, Helen White, PhD, Oliver Giles Best, PhD, Nick Cross, PhD, Jelena Mann, PhD, Mathias Ehrich, MD, David Graham Oscier, MD
Journal: Blood
Blood (2008) 112 (11): 2246.
https://doi.org/10.1182/blood.V112.11.2246.2246
Published: 2008
Journal Articles

A Novel Functional Assay Using Etoposide Plus Nutlin 3, FISH and Mutational Analysis Detects Heterogeneity of ATM/p53 Pathway Alterations in CLL.

Giles Best, PhD, Anne Gardiner, BSc, Rachel Ibbotson, PhD, Aneela Majid, PhD, Renata Walewska, MD, Belinda Austen, MD, Tanja Stankovic, PhD, Martin Dyer, MD, David Graham Oscier, MD
Journal: Blood
Blood (2006) 108 (11): 2795.
https://doi.org/10.1182/blood.V108.11.2795.2795
Published: 2006
Journal Articles

Defining the 10 Year Risk of Disease Progression in Stage A0 CLL.

Anne Gardiner, BSc, Zadie Davis, MSc, Parker Anton, BSc, Giles Best, PhD, Rachel Ibbotson, PhD, Sarah Mould, BSc, Sharron Glide, BSc, Peter Thomas, PhD, Jenny Orchard, MD, David Graham Oscier, MD
Journal: Blood
Blood (2006) 108 (11): 2772.
https://doi.org/10.1182/blood.V108.11.2772.2772
Published: 2006
Journal Articles

Prognostic Factors in the UK LRF CLL4 Trial.

David Graham Oscier, MD, Rachel Wade, MSc, Jenny Orchard, MD, Zadie Davis, MSc, Giles Best, PhD, Alison Morilla, BSc, Vasantha Brito-Bapapulle, PhD, Estella Matutes, MD, Sue Richards, DPhil, Daniel Catovsky, MD
Journal: Blood
Blood (2006) 108 (11): 299.
https://doi.org/10.1182/blood.V108.11.299.299
Published: 2006
Journal Articles

Prognostic Factors in the UK LRF CLL4 Trial.

David Graham Oscier, MD, Sue Richards, DPhil, Jenny Orchard, MD, Zadie Davis, MSc, Giles Best, PhD, Alison Morilla, BSc, Vasantha Brito-Bapapulle, PhD, Estella Matutes, MD, Andrew Pettitt, MD, Daniel Catovsky, MD
Journal: Blood
Blood (2005) 106 (11): 2099.
https://doi.org/10.1182/blood.V106.11.2099.2099
Published: 2005